Cargando…
Inducible scAAV2.GRE.MMP1 lowers IOP long-term in a large animal model for steroid-induced glaucoma gene therapy
Current treatment of glaucoma relies on administration of daily drops or eye surgery. A gene therapy approach to treat steroid-induced glaucoma would bring a resolution to millions of people worldwide that depend on glucocorticoid therapy for a myriad of inflammatory disorders. Previously, we had ch...
Autores principales: | Borrás, Teresa, Buie, LaKisha K., Spiga, Maria Grazia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860029/ https://www.ncbi.nlm.nih.gov/pubmed/26855269 http://dx.doi.org/10.1038/gt.2016.14 |
Ejemplares similares
-
Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques
por: Dehay, Benjamin, et al.
Publicado: (2012) -
Nonclinical Safety Evaluation of scAAV8-RLBP1 for Treatment of RLBP1 Retinitis Pigmentosa
por: MacLachlan, Timothy K., et al.
Publicado: (2017) -
Targeting the Root Cause of Mucopolysaccharidosis IIIA with a New scAAV9 Gene Replacement Vector
por: Bobo, Tierra A., et al.
Publicado: (2020) -
Intracisternal delivery of NFκB-inducible scAAV2/9 reveals locoregional neuroinflammation induced by systemic kainic acid treatment
por: Bockstael, Olivier, et al.
Publicado: (2014) -
Cystatin A, a Potential Common Link for Mutant Myocilin Causative Glaucoma
por: Kennedy, K. David, et al.
Publicado: (2012)